Multiple Myeloma

The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.

Latest News

Multiple myeloma words appearing on table | Image credit: ibreakstock - stock.adobe.com
Lower Tregs Linked With Survival in Multiple Myeloma

July 1st 2025

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a higher percentage of regulatory T cells (Tregs).

These studies highlight that multiple myeloma outcomes are not solely determined by disease biology or available therapies. | Image Credit: wladimir1804 - stock.adobe.com
Highlighting Disparities in Myeloma Outcomes, the Impacts of Comorbidities

June 28th 2025

Westin Forrestal Princeton | Image: Westin
Value-Based Care Calls for Putting Novel Therapies Closer to Patients

June 19th 2025

Mansi Shah, MD
Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

June 11th 2025

The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com
Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

June 7th 2025

Experts Weigh in on Multiple Myeloma

Explore the expanding role of bispecific antibody therapies and strategies for managing cytokine release syndrome and infection risks. Dive into real-world data on teclistamab and talquetamab, and uncover new approaches to optimize patient outcomes.

AJMC Insights logo displayed on a blue abstract background with light and dark wave patterns.
Continuing Medical Education
View All
July 6th 2025

Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care

1.5 Credits / Hematology, Hematologic Cancer, Oncology
July 6th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 6th 2025

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.5 Credit / Hematologic Cancer, Oncology
July 6th 2025

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.0 Credit / Oncology, Hematology, Hematologic Cancer
July 6th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
July 6th 2025

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

1.5 Credits / Hematologic Cancer, Hematology, Oncology

More News

Multiple myeloma blood testing | Image credit: luchschenF - stock.adobe.com
November 29th 2023

Belantamab Mafodotin Improves PFS in Relapsed/Refractory Multiple Myeloma

Hayley Virgil
Second-line treatment with belantamab mafodotin plus bortezomib/dexamethasone in patients with relapsed/refractory multiple myeloma is supported by findings from the phase 3 DREAMM-7 study.
Patient in the hospital | Image credit: Tyler Olson - stock.adobe.com
November 22nd 2023

Minimizing Terms for Toxicity Often Used in Multiple Myeloma Trials, Study Says

Rose McNulty
A cohort study of 65 clinical trials in multiple myeloma found that toxic effects are often described with subjective terminology that may not reflect adverse event rates reported in the studies.
Multiple myeloma blood testing | Image credit: luchschenF - stock.adobe.com
November 17th 2023

Interactions Between Tumor Genes, Microenvironment Impact Treatment Response in Multiple Myeloma

Gillian McGovern
The study findings provide the first in-depth look at the relationship between chromosomal changes in tumor cells and immune components of the tumor microenvironment.
Cardiovascular system | Image credit: appledesign - stock.adobe.com
November 10th 2023

CHIP Present Before HCT Linked With Later CVD Risk in Multiple Myeloma

Rose McNulty
The findings suggest the presence of CHIP before HCT may have potential to serve as a biomarker for CVD risk after HCT in patients with multiple myeloma.
Multiple myeloma | Image credit: David Litman - stock.adobe.com
November 2nd 2023

CAR T-Cell Therapy Responses Differ by Race and Ethnicity, Study Finds

Sabrina Serani
While response and safety may vary across racial and ethnic subgroups, progression-free survival and overall survival does not appear to differ when chimeric antigen receptor T-cell therapy is used in the treatment of patients with multiple myeloma.
Illustration of T cells | Image credit: Sebastian - stock.adobe.com
October 30th 2023

Study Identifies Mechanisms of Resistance to Immunotherapy for Multiple Myeloma

Rose McNulty
Investigators found that myeloma cells may lose or change targets and subsequently go undetected by these therapies, suggesting that screening for such changes regularly could help guide treatment.
Ixazomib molecule | Image credit: molekuul.be - stock.adobe.com
October 28th 2023

Ixazomib Shows Efficacy, Tolerability in Real-World R/R Multiple Myeloma Treatment

Rose McNulty
A study of patients with relapsed or refractory (R/R) multiple myeloma who received ixazomib-based therapy in real-world settings found the treatment effective and tolerable in clinical practice.
CAR T cell | Image credit: Alpha Tauri 3D - stock.adobe.com
October 27th 2023

Cilta-Cel Leads to High PFS Rates in Patients With Multiple Myeloma and Poor Prognostic Features

Courtney Flaherty
Patients with multiple myeloma exhibiting poor prognostic features, such as high-risk cytogenetics, soft-tissue plasmacytoma, ISS stage III disease, and triple-class exposure, experienced significant progression-free survival benefit with ciltacabtagene autoleucel.
Multiple myeloma cells | Image credit: David A Litman - stock.adobe.com
October 26th 2023

Early Relapse Shows Powerful Prognostic Value in Multiple Myeloma

Rose McNulty
Researchers identified an optimal early relapse time point to incorporate into traditional risk features and formed a novel prognostic classification utilizing both static and dynamic risk.
Multiple myeloma | Image credit: ibreakstock - stock.adobe.com
October 20th 2023

Intensive Therapy More Effective vs Less Intense Therapy in Frail Patients With MM

Rose McNulty
A recent study suggests that more intensive triplet therapy is more effective than less intensive doublet therapy in frail patients with newly diagnosed multiple myeloma (MM), and that more intensive treatment may even improve frailty itself.
Blood Cells | Image credit: Катерина Євтехова - stock.adobe.com.jpg
October 13th 2023

Immunotherapy Sequences May Lead to Disease Resistance/Relapse in Myeloma

Conor Killmurray
BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents.
Immune cells attacking cancer | Image credit: Spectral-Design - stock.adobe.com
October 6th 2023

Immune System Traits Linked With Remission in Multiple Myeloma

Rose McNulty
A recent study suggests that a patient’s immune microenvironment plays a key role in the depth and duration of response to multiple myeloma treatment.
Nurse helping man exercise | Image credit: Studio Romantic - stock.adobe.com
September 28th 2023

Physical Activity Improves Performance, Frailty Scores, PROs in Multiple Myeloma

Morgan Bayer
Exercises such as resistance training and walking were safe and effective interventions that were associated with improved frailty scores and patient-reported outcomes (PROs) in patients with multiple myeloma receiving systemic treatment.
Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com
September 22nd 2023

Many Factors Influence Selection of CAR T Therapy, Bispecifics in Myeloma

Kyle Doherty
Bispecific antibodies may be more broadly applicable as treatment for patients with multiple myeloma in the short-term, according to Ajai Chari, MD.
Blood cells | Image credit: flashmovie - stock.adobe.com
September 20th 2023

Despite Treatment Improvements, Second Primary Malignancies Adversely Affect MM Prognosis

Rose McNulty
In a real-world study using data from patients diagnosed with multiple myeloma between 2009 and 2021, second primary malignancies adversely impacted survival outcomes in the modern era of therapeutics.
FDA Approved | Image credit: Olivier Le Moal - stock.adobe.com
September 12th 2023

FDA Approves Motixafortide Plus Filgrastim for Stem Cell Mobilization in Multiple Myeloma

Rose McNulty
The combination therapy is the first FDA approved for the mobilization of hematopoietic stem cells prior to autologous transplantation in patients with multiple myeloma.
dr jordan berlin
September 5th 2023

Dr Jordan Berlin Discusses Precision Medicine and Factoring Patient Preferences Into Treatment

Brooke McCormick
Jordan Berlin, MD, FASCO, of Vanderbilt University Medical Center, explained how patient preferences and new treatments are considered, as well as what he is currently working on and his biggest takeaway from The American Journal of Managed Care®’s Institute for Value-Based Medicine® held in Nashville, TN on August 17, 2023.
Dr Joseph Mikhael
August 28th 2023

Dr Joseph Mikhael on Strategies to Increase Diversity in Multiple Myeloma Trials

Skylar Jeremias
Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, highlights several potential strategies to address the historic lack of diversity in multiple myeloma clinical trial populations.
LASZLO - stock.adobe.com
August 26th 2023

Study Suggests CAR T-Cell Therapy Safe, Effective After Allo-SCT in Multiple Myeloma

Rose McNulty
A retrospective analysis of the CARTITUDE-1 trial suggests that patients who have undergone allogeneic stem cell transplant (allo-SCT) prior to receiving chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma experience comparable outcomes to allo-SCT–naïve patients.
Dr Joseph Mikhael: Researchers, Organizations Must Collaborate to Address Disparities in Multiple Myeloma
August 23rd 2023

Dr Joseph Mikhael: Researchers, Organizations Must Collaborate to Address Disparities in Multiple Myeloma

Skylar Jeremias
Researchers and organizations must collaborate to address the persistent disparities in access to treatments for multiple myeloma, explained Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation.
Red FDA approved stamp on white background
August 14th 2023

FDA Approves Elranatamab for Relapsed or Refractory Multiple Myeloma

Kristi Rosa
The FDA has granted accelerated approval to elranatamab-bcmm (Elrexfio) for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously received at least 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
FDA approval
August 10th 2023

FDA Grants Talquetamab Accelerated Approval for R/R Multiple Myeloma

Ariana Pelosci
Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.
Calendar
August 4th 2023

Later, Deeper Multiple Myeloma Treatment Responses Linked to Improved Outcomes

Rose McNulty
The study also found that patients with a later best confirmed response to therapy demonstrated improved outcomes compared with patients who experienced an early best confirmed response.
Appointment Reminder to Calendar and Organizer Agenda: © onephoto - stock.adobe.com
July 27th 2023

MM Therapy Attrition Not as High as Previously Reported

Jared Kaltwasser
Fewer patients opt to skip therapy for their multiple myeloma (MM) despite progressive disease than previously thought, a new study suggests.
Case Study Education concept. Analysis of the situation to find a solution: © Funtap - stock.adobe.com
July 25th 2023

Patient Presents With Hyperammonemia After Complete MM Remission in Rare Case

Gianna Melillo
The individual first received their multiple myeloma (MM) diagnosis in 2019.
Doctor holding a sign reading Multiple Myeloma
July 18th 2023

Dr Hans Lee Discusses Infection Mitigation Strategies for MM Treated With CAR T or Bispecific Antibodies

Laura Joszt, MA Skylar Jeremias
Bispecific antibodies or chimeric antigen receptor (CAR) T-cell therapies are both associated with an increased risk of infection for patients with multiple myeloma (MM), explained Hans Lee, MD, of The University of Texas MD Anderson Cancer Center.
stethoscope, red ribbon and colored paper with the word Multiple Myeloma. medical and patient concepts: © Fauzi - stock.adobe.com
July 14th 2023

Need for More Research on Young Patients With Multiple Myeloma

Gianna Melillo
Authors defined any patient 50 years or younger as a “young” patient.
desperate man sitting at hospital bed alone sad and devastated: © Wordley Calvo Stock - stock.adobe.com
July 11th 2023

ERBB2/HER2 Upregulated in MM, Higher Levels Associated With Poor Outcomes

Jared Kaltwasser
The findings suggest existing therapies for other cancers may be helpful in multiple myeloma (MM).
Back pain, kidney inflammation, man suffering from backache at home: © staras - stock.adobe.com
July 8th 2023

Unique Multiple Myeloma Presentation Highlighted in New Case Study

Gianna Melillo
Symptoms initially pointed to toxic alcohol ingestion.
Multiple myeloma. Doctor shows sign/board with wooden frame. Background blue: © MQ-Illustrations - stock.adobe.com
July 6th 2023

Review Details Racial/Ethnic Disparities in MM, Offers Guidance for Improvement

Gianna Melillo
Improving culturally responsive care and practicing cultural humility can help health care providers deliver equitable care for all patients living with multiple myeloma (MM).
<123456789
...
12>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo